What may ease a sore, stiff shoulder

What to try for relief now

Move the arm gently without fighting its firm stopping point. Physical therapy can teach stretches that fit your current movement.

It may also help you keep dressing and bathing on your own. Don’t force a stretch, because harder isn’t always better.

Some medicines can ease soreness for a short time. Your doctor can check them against the medicines you already take.

A steroid treatment may help briefly, but relief can fade. It can ease pain without making the shoulder recover sooner.

Which choice works fastest? Medical studies haven’t found one choice that works fastest for everyone.

What to ask if relief doesn’t last

If early relief fades, ask what the next choice may change. Better sleep may matter more than reaching a high shelf.

Ask how many visits are likely and what each visit checks. Get the cost before any care begins.

Surgery may help some stiff shoulders, but it has risks. Medical studies don’t show one main treatment working for everyone.

Ask how long any expected relief usually lasts. Also ask what happens if the soreness doesn’t change.

The answer needs to fit your exam and daily needs. Then you can weigh relief, travel, cost, and risk.

Sources

1. At 10 years, arthroscopic subacromial decompression offered NO benefit over placebo surgery for subacromial pain syndrome: the mean difference in VAS pain was -1.5 points (95% CI -8.6 to 5.6) at rest and -3.2 points (-13.0 to 6.5) on arm activity, against a minimally important difference of 15. It also showed no benefit over exercise therapy.

   Kanto K, et al. — Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trial.. BMJ, 2025. DOI: 10.1136/bmj-2025-086201.

2. UK FROST randomized 503 adults with primary frozen shoulder to manipulation under anaesthesia, arthroscopic capsular release, or early structured physiotherapy with steroid injection. At 12 months every between-group difference on the Oxford Shoulder Score was smaller than the target difference, so NONE of the three was clinically superior. Capsular release carried the most serious adverse events (8 versus 2 with manipulation), and manipulation under anaesthesia was the most cost-effective.

   Rangan A, et al. — Management of adults with primary frozen shoulder in secondary care (UK FROST): a multicentre, pragmatic, three-arm, superiority randomised clinical trial.. Lancet, 2020. DOI: 10.1016/S0140-6736(20)31965-6.

3. A systematic review of nine randomized trials of primary frozen shoulder found that none of physiotherapy-with-steroid-injection, manipulation under anaesthesia or arthroscopic capsular release is clinically superior to the others; all standardized mean differences fell below the clinical-significance threshold agreed for UK FROST and most confidence intervals included zero. The evidence for HYDRODILATATION was inconclusive and remains a gap.

   Rex SS, et al. — Effectiveness of interventions for the management of primary frozen shoulder : a systematic review of randomized trials.. Bone Jt Open, 2021. DOI: 10.1302/2633-1462.29.BJO-2021-0060.R1.

4. The Cochrane review of corticosteroid injections for shoulder pain included 26 trials (median 52 participants each) and concluded there is LITTLE overall evidence to guide treatment: subacromial injection for rotator cuff disease showed a small benefit over placebo in some trials but no benefit over NSAIDs when three trials were pooled, and intra-articular injection for adhesive capsulitis showed a possible early benefit that was 'small and not well-maintained'.

   Buchbinder R, et al. — Corticosteroid injections for shoulder pain.. Cochrane Database Syst Rev, 2003. DOI: 10.1002/14651858.CD004016.

5. The Cochrane review of manual therapy and exercise for adhesive capsulitis included 32 trials and 1,836 participants and found NO trial comparing the combination against placebo or no intervention. Moderate-quality evidence showed six weeks of manual therapy plus exercise produced LESS improvement at seven weeks than glucocorticoid injection (pain change 32 versus 58 points on a 100-point scale; function 14 versus 39 points), with similar adverse events.

   Page MJ, et al. — Manual therapy and exercise for adhesive capsulitis (frozen shoulder).. Cochrane Database Syst Rev, 2014. DOI: 10.1002/14651858.CD011275.

6. A 2026 meta-analysis of eight level-I randomized trials (452 patients) found SUPRASCAPULAR NERVE BLOCK superior to intra-articular corticosteroid injection for adhesive capsulitis pain at 3-4 weeks (SMD 0.63), 6-7 weeks (SMD 0.49) and 12 weeks (SMD 1.68), and superior on SPADI and active abduction (+14.4 degrees) at 12 weeks. Heterogeneity was considerable for every analysis.

   Harley JD, et al. — Intra-articular corticosteroid injection vs. suprascapular nerve block for adhesive capsulitis: a systematic review and meta-analysis of level I randomized controlled trials.. J Shoulder Elbow Surg, 2026. DOI: 10.1016/j.jse.2025.05.037.

7. A systematic review of six randomized trials (410 shoulders) of hydrodilatation ADDED to corticosteroid injection for adhesive capsulitis found the evidence split: two trials showed clinically and statistically significant benefit at 3 months and one showed benefit on some measures, while THREE showed no benefit over corticosteroid injection alone. Any advantage appears concentrated in the first three months.

   Catapano M, et al. — Hydrodilatation With Corticosteroid for the Treatment of Adhesive Capsulitis: A Systematic Review.. PM R, 2018. DOI: 10.1016/j.pmrj.2017.10.013.

8. FDA states verbatim that stem cell, stromal vascular fraction, umbilical cord blood, Wharton's jelly, amniotic fluid and exosome products 'have [not] been approved for the treatment of any orthopedic condition, such as osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain, or shoulder pain.' The only FDA-approved stem cell products in the United States are blood-forming (hematopoietic progenitor) cells from umbilical cord blood, approved only for disorders of blood production, and there are currently NO FDA-approved exosome products.

   U.S. Food and Drug Administration — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA (Center for Biologics Evaluation and Research), 2020.

9. A 2025 systematic review of 1,125 patients receiving intra-articular injections for glenohumeral osteoarthritis reported a 7.2% overall complication rate and a 3.2% rate of proceeding to surgery. Hyaluronic acid showed consistent though modest benefit, while the evidence for ORTHOBIOLOGICS (PRP, bone marrow aspirate concentrate, mesenchymal stem cells) 'remains limited', mainly because of heterogeneity in design, outcomes and patient characteristics.

   Migliorini F, et al. — Intra-articular injections for shoulder arthritis in adults: a systematic review.. Eur J Med Res, 2025. DOI: 10.1186/s40001-025-03423-4.

10. Medicare's national coverage policy covers autologous platelet-rich plasma ONLY for chronic non-healing diabetic, pressure and/or venous wounds, and only within an approved coverage-with-evidence-development study. There is no Medicare national coverage for PRP in shoulder osteoarthritis or rotator cuff disease, which is why these injections are billed to the patient directly.

    Centers for Medicare & Medicaid Services — Autologous Platelet-rich Plasma (Coverage with Evidence Development). CMS.gov, 2024.

11. In January 2025 federal court orders permanently BANNED the co-founders of the Stem Cell Institute of America and related companies from marketing stem cell therapy and imposed $5,155,146 in civil penalties and consumer refunds. The court found on summary judgment that they published false and misleading advertisements about the efficacy and approval of stem cell injections for conditions including osteoarthritis; the affiliated clinic charged up to $5,000 per injection, almost entirely to elderly and disabled consumers.

    Federal Trade Commission — Stem Cell Institute Co-Founders and Companies Banned from Marketing Stem Cell Treatments and Ordered to Pay More Than $5.1 Million for Refunds and Civil Penalties. FTC Press Release, 2025.